NCT07390253Active, not recruiting
Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration
Aflibercept 8mg in Patients Diagnosed With Neovascular Age-related Macular Degeneration (AMD) Who Have Been Treated With Aflibercept 2mg: the Eylea 8mg Switch Study
Source: ClinicalTrials.gov · Last updated 17 Feb 2026
Brief summary (registry, in English)
This study will investigate if switching patients who appear to be sub-optimal responders to the current standard of care treatment with Aflibercept 2mg to Aflibercept 8mg will prolong treatment intervals and maintain visual acuity.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 50 (estimated)
- First submitted
- 28 Jan 2026
- Start date
- 18 Sept 2024
- Primary completion date
- 1 Feb 2026
- Lead sponsor
- Vienna Institute for Research in Ocular Surgery
- Diseases
- Macular degeneration
- NCT number
- NCT07390253
What you commit to
- Study type: Observational
- Planned participants: 50
- From 18 Sept 2024 to the primary completion date, 1 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Chronic treatment with Bevacizumab or Faricimab
- Prior Aflibercept 8mg treatment
Other illness
- Vitreous hemorrhage
- Ocular or periocular infections
- Hypersensitivity to the active substance or to any of the excipients
Age
- Pregnancy (for women in reproductive age a pregnancy test will be performed)
Other
- Extensive macular fibrosis
- Diabetic retinopathy
- Other retinal pathologies (e.g. retinal vein occlusion)
- Dense media opacities (cataract, corneal scars)
- Active intraocular inflammation
Who the study is looking for
- Patients, who received prior intravitreal anti-VEGF-treatment for nAMD with Aflibercept 2mg. A minimum of four injections of Aflibercept 2mg is required. Therefore 16-24 weeks prior treatment with anti-VEGF is required in line with an interval of 4-8 weeks.
- Short treatment intervals of 4 or 8 weeks
- nAMD
- Age 21 or older
- Written informed consent
Age in the registry: 21 years to 105 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Vienna Institute for Research in Ocular Surgery Coordinator of this site? Confirm its status | Vienna | Austria | Unknown status |
Related publications
- Prospective Real-World Outcomes After Switching to Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration with High Treatment Burden.Ophthalmol Ther · 2026 · PMID 42154394
This page is information, not medical advice. Discuss any trial with your doctor.